If you have Gaucher disease, you may be able to participate in a clinical trial that is taking a deeper look into how the disease is treated. Read more to find out how you can get involved today!See if you qualify →
The SHP-GCB-402 Gaucher clinical research study is evaluating the effect velaglucerase alfa (VPRIV®) has on bone pain and bone density in people with type I Gaucher disease.
If you have type I Gaucher disease, glucocerebroside (a fatty substance) builds up in your body because you lack the enzyme glucocerebrosidase, which is needed to break it down. When this substance accumulates in your bone marrow (a spongy tissue filling the bones) it leads to loss of bone density and possible broken bones, as well as extreme pain.
The approved medication, velaglucerase alfa (VPRIV®) is a prescription medication indicated for long-term enzyme replacement therapy (ERT) for patients with type I Gaucher disease.
While receiving VPRIV®, participants will visit a study clinic approximately 14 times throughout the study. During the dosing period, these visits will be once every 3 months.
The study medication will be administered as a 60-minute intravenous (IV) infusion (a drip) once every 2 weeks. The first 3 doses will be administered at a study clinic. All doses from thereon may be administered at the participant’s home by a member of the study team, if the study doctor (investigator) sees fit. Overall, participants will receive 51 infusions over the course of 102 weeks. In addition to receiving IV infusions, the study doctor will assess and monitor participants’ general health. All study-related office visits, medical examinations, and study medication will be provided to qualified study participants at no cost to them.
You may also be eligible for home infusions starting at Week 7. You will need to return to the study clinic for visits that include medical imaging.